EVR RX v.s. HL NYC RX
Title. Which offer would you pick if you have both? Both are for SA 2024 and in the NYC office. Thank you!
Trending Content - Investment Banking Forum
| +183 | Evercore > Goldman and I don’t think it’s particularly close anymore | 65 | 1h |
| +156 | Article: Why UBS's Asian M&A bankers are thriving and UBS's American M&A bankers are not | 17 | 22h |
| +130 | I am a drunk MD AMA | 40 | 2d |
| +87 | UBS Offer Day | 30 | 1d |
| +75 | Santander IB? | 10 | 3d |
| +71 | I hate Wells Fargo | 19 | 1d |
| +59 | Think Twice before Recruiting for HOUSTON IB!! | 30 | 16m |
| +51 | No return offer - feeling like a failure is an understatement | 20 | 19h |
| +48 | How cooked am I as an incoming WF IB SA 2027? | 17 | 16h |
| +46 | WF Return offers | 28 | 2d |
Career Resources
.
Bump, any material difference between these two?
They're both elite groups - pick based on who you vibed with more.
If all else is strictly indistinguishable then I would pick EVR - way better firm recognition (outside of those who know Rx) and the group is killing it right now.
Evercore: stronger name outside of finance, higher pay
Houlihan: stronger name in RX, better hours
First criteria is fit. Both are excellent names and you can't go wrong with either, so do the one where you can see yourself getting along with others in the bullpen.
If you're completely indifferent fit-wise, would choose EVR RX. Viewed as a better analyst program and will work with smarter kids.
If your a hardo for RX, go HL RX. Historically the #1 player in the space. Sure evercore as a firm overall is more prestigious, but HL RX is still top dog.
i thought pjt was #1 cuz they’re more debtor side and HL more creditor side, am i misguided?
I would argue EVR is better considering they do debtor work. HL Rx is just a volume creditor shop. They have like 200 rx employees while everyone else has max 40.
Don’t know why this forum has a hard-on for HL Rx. The experience you get there would be worse than any EB Rx, unless you’re staffed on their premier deals.
HL has a stronger global presence than other EB RX groups, hence the bigger group size. If we are talking about HL RX in the US, the split between debtor and creditor work is roughly 50-50. HL RX is also known for offering one of the best group culture and analyst experience on the street. You clearly have no idea what you are talking about, prospect.
You clearly work at HL. You can even see in Rx league tables they have 4x the group size yet in Q4 2022 they had 50% of the dollar volume advised than everyone else lmao.
HL does nothing special they are once again a volume shop, they are a solid shop but definitely below in terms of EB experience. Once again if you aren’t the top analyst you are going to be staffed on some BS creditor work of a company with a $25m capital structure. Evercore/Lazard are above HL Rx.
Depends on who you know and how well you connected. Same shit, different wrapper.
If you don't understand this, you don't go to a top target or are some random person.
8 SB in 18 minutes tf? Imagine making fake accounts to tip the scale in a dumb pissing contest.
Not a take I've heard from any of the rx people at my top target. Other than the kind of shitty offer timeline, care to elaborate why?
Inaccurate. I personally know a Penn kid (JWS, so I’d argue they’re pretty top tier) that is returning + another JWS who is incoming SA.
Did you ask either of the teams about their on-cycle exits this year? I found both EVR and Laz higher ups happy to discuss and proud
Not sure about other offices but HL NY has had recent (last 2-3 years) exits to SPC, Oaktree, APO, BX, KKR, Centerbridge, with multiple analysts heading to several of the listed funds. From an exits perspective they're right up there with EVR and probably outdo Lazard, although they're definitely a step below PJT, which has had a consistent pipeline to APO PE.
League table argument is moot given a majority of the mandates these shops land are out-of-court, but HL does seem to be losing larger mandates to PJT and EVR. I'd venture to guess that analyst experience in NY is closer to PJT/EVR/LAZ/MOE, but probably not comparable for HL analysts in the satellite office.
Not on a per-capita basis. HL has significantly 2-3x RX class sizes compared to EVR's 6-7 but the same or worse absolute # of exits.
Can confirm that HL RX has been killing it in terms of exits. I’d say they also have a pretty strong Apollo pipeline, both PE and HVF.
I love how where Wharton kids would go is like a real criteria to evaluate how prestigious an offer is
thoughts on HL LA vs NY (RX)?
The winters are colder in NY vs LA, just my take as an intern
Big if true
evr M&A make sense but HL Rx over evr rx anyday.
EVR RX has surpassed HL RX, but HL NY is still an incredibly strong group with great exits
Would anyone be able to comment on the London version of this thread? EVR RX vs HL RX (London)? And why?
Neither. Only Rx office or really IBD program in general worth doing is PJT. Take your talents to Wendy's
Voluptatem quas quis minima non quo corporis magni. Nihil nesciunt voluptatum ea vero molestiae et rerum.
Id minima perferendis earum voluptatem molestias dolorem eum. Facilis et et saepe fugit placeat. Quaerat fuga corrupti consequatur est deleniti voluptatem. Quae quis ut ut enim consequatur quos consequatur culpa.
Hic nobis aut explicabo commodi qui consequatur quaerat. Qui at rem ex. Voluptas quis omnis ut non.
Provident voluptatem itaque ut in incidunt. Hic dolores veritatis sit hic ut nemo. Consectetur consequatur qui blanditiis harum quia molestiae aut. Est deleniti aut et et animi. Cupiditate eum suscipit illum dolor non nam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...
Eos et assumenda sunt sequi aliquam. Provident omnis ut consequatur quaerat voluptate aut. Eveniet enim minus natus dolore quia. Officia vero quia debitis incidunt laboriosam.
Numquam sunt et ipsam aut deleniti qui quo. Rerum est rerum est. Molestias et eligendi earum doloremque magnam voluptate. Voluptas sint est est laudantium veniam et. Eum veniam consequatur omnis saepe.
Aut laborum ducimus tempora. Officia sequi animi nihil hic iste assumenda. Enim qui mollitia inventore dignissimos. Deleniti autem vitae et ut. Sequi at inventore aut incidunt.
Esse illo vitae cum itaque velit ut. Veritatis perspiciatis consequatur doloremque placeat nobis ipsa. Commodi ut veniam eveniet iste ipsa necessitatibus quibusdam. Eligendi distinctio modi soluta vitae.